Targeted delivery for regenerative medicines: an untapped opportunity for drug conjugates
| Autor: | Malin Lemurell, Eric Valeur, Maria Ölwegård-Halvarsson, Laurent Knerr |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Pharmacology Drug medicine.medical_specialty business.industry media_common.quotation_subject 010402 general chemistry Regenerative Medicine 01 natural sciences Regenerative medicine 0104 chemical sciences 03 medical and health sciences 030104 developmental biology Drug Delivery Systems Pharmaceutical Preparations Neoplasms Drug Discovery medicine Humans Intensive care medicine business Site of action media_common |
| Zdroj: | Drug discovery today. 22(6) |
| ISSN: | 1878-5832 |
| Popis: | Regenerative approaches are promising avenues to effectively cure diseases rather than merely treating symptoms, but are associated with concerns around proliferation in other organs. Given that targeted delivery holds the promise of delivering a drug precisely to its desired site of action, usually with the prospect of increasing the therapeutic index, it can be considered as an essential enabler of regenerative medicines. Although significant progress has been made predominantly in oncology for the delivery of cytotoxic drugs using antibody-drug conjugates (ADCs), the physiological conditions and safety requirements for regenerative medicines are very different. Drug conjugates need to be approached differently and, we herein suggest using a broader range of homing modalities and a specific framework to develop safe linkers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect